AstraZeneca Plans Spin-offs and Announces Cancer Progress

25.04.2014 - AstraZeneca has unveiled plans to sell or partner infection and neuroscience units with combined 2013 sales of $3.5 billion and a basis in antibiotics and antipsychotics as well as...